Endpoints 20 under 40; Verdict on PI3K; Regeneron goes discount shopping; $1.85B deal implodes; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
The Endpoints News team is really growing. We’re excited to welcome Lei Lei Wu and Tyler Patchen joining as our newest reporters. For an illustration of what a diverse set of writers could bring, look no further than this year’s Endpoints 20 under 40 — the perspectives and accents that everyone brings are simply incredible. I hope you enjoy reading the special report as much as I did.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.